Comment from BD (Becton, Dickinson and Company)

Summary: BD (Becton, Dickinson and Company), a global medical technology company, supports the draft guidance for clarifying the process for responding to FDA Form 483 observations. They provide specific recommendations to clarify the optional nature of responding to verbal observations, establish a transparent review timeline, and improve communication regarding contested scientific or technical disagreements.